European Heart Journal - McMaster Experts

publication venue for

Androgen deprivation therapy for prostate cancer, measures of adiposity and strength, and adverse cardiovascular outcomes: observations from 3000 men in 5 countries in the RADICAL PC study 2023
Machine learning to predict myocardial injury and death after non-cardiac surgery 2023
Myocardial injury in hip fractures: a HIP ATTACK-1 randomized trial substudy 2023
Contrasting patterns of symptoms compared to mortality in women and men with Congestive Heart Failure (the G-CHF registry) 2023
A prediction model for ventricular tachycardia events using 24h ambulatory ECG 2022
Body mass index from the RE-LY trial: further evidence of the obesity paradox 2022
Dual versus single antiplatelet therapy after transcatheter aortic valve replacement: a systematic review and meta-analysis 2022
End-of-trial inflammatory biomarkers, lipid levels, creatine kinase and markers of renal and liver function in the LoDoCo2 trial 2022
Factors associated with health-related quality of life in heart failure in 23,000 patients from 40 countries: results of the global congestive heart failure research program 2022
The effects of colchicine in patients with diabetes mellitus and chronic coronary artery disease: a post-hoc analysis of the LoDoCo2-trial 2022
Bradycardia associated with ALK inhibitors in the treatment of non-small cell lung cancers: a systematic review and meta-analysis 2021
Cardiovascular events among recipients of hematopoietic stem cell transplantation 2021
Cardiovascular events among recipients of hematopoietic stem cell transplantation 2021
Evaluating direct oral anticoagulants versus vitamin K antagonists for treatment of left ventricular thrombus: a systematic review and meta-analysis 2021
Fingerprint of novel circulating microRNAs identify patients with stroke-embolic stroke of undetermined source 2021
Anticoagulation for mechanical aortic valve replacement: an international survey 2020
Antiplatelet therapy prescription patterns for acute coronary syndrome: a decade analysed 2020
Association of a history of falls or syncope with intracranial bleeding in patients with atrial fibrillation 2020
CHA2DS2-VASc and CHADS2 scores for risk stratification of major adverse cardiovascular events in the COMPASS trial 2020
Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR and albuminuria: a REWIND post hoc subgroup analysis 2020
Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial 2020
Efficacy and safety of low-dose rivaroxaban on top of aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial 2020
Efficacy of betablockers in patients with acute coronary syndrome: a systematic review and meta analysis of randomized trials 2020
High-sensitivity troponin I predicts major cardiovascular events after noncardiac surgery 2020
Incidence and risk of short episodes of atrial fibrillation detected with 14 days of continuous electrocardiographic monitoring 2020
Microvascular disease, peripheral artery disease, and the risk of lower limb amputation 2020
Perioperative atrial fibrillation and risk of stroke after cardiac surgery: a systematic review and meta-analysis 2020
The effect of computer decision support on optimizing appropriate dosing of novel oral anticoagulant therapy in the IMPACT-AF study 2020
Vitamin K antagonists versus direct oral anticoagulants after cardiac surgery: a 31-country cohort study 2020
A point-of-care risk score predicts 30-day readmission in patients hospitalized with heart failure (HF): derivation and validation of the LENT index 2019
Diabetes mellitus is a risk factor for ischemic stroke in patients with and without coronary artery disease after coronary angiography 2019
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial 2019
Evaluation of the pharmacodynamics of a ticagrelor reversal agent PB2452 2019
Intensity and cost of health care at the end of life among patients with heart failure 2019
Risk factors and clinical outcomes in chronic CAD and PAD: an analysis of the randomized, double-blind COMPASS trial 2019
Sex-based disparities in end of life care among patients with heart failure 2019
The applicability of the dual pathway approach criteria after coronary angiography 2019
Thrombotic events in bleeding patients treated with andexanet alpha: an ANNEXA-4 sub-study 2019
A novel model for prediction of ischemic stroke in patients without atrial fibrillation 2018
AMPK-ACC signaling modulates platelet phospholipids content and potentiate platelet function and thrombus formation 2018
All you need is LE: utility of an abbreviated LACE score in predicting 30-day outcomes among patients hospitalized for Heart Failure (HF) 2018
Applicability of the COMPASS trial in a Danish all-comers coronary angiography cohort: an analysis of the Western Denmark heart registry 2018
Benzodiazepine-free cardiac anesthesia for reduction of delirium (B-Free): a two-centre pilot study to determine the feasibility of a multi-centre, randomized, cluster crossover trial 2018
Effect of free testosterone levels on cardiovascular outcomes: a Mendelian randomization analysis 2018
Electrophysiological characteristics of A1294G substitution in Nav1.5 channel, associated with combined clinical phenotype 2018
Outcome after ross procedure in adult patients: a systematic review, meta-analysis and microsimulation 2018
PROCAM vs. SCORE: 10 years after 2018
Predicting risk at the point of care: NT-proBNP improves performance of the LACE index among patients hospitalized for Heart Failure (HF) 2018
Reversal of apixaban and rivaroxaban anticoagulation by andexanet alfa in ANNEXA-A&R as assessed by non-tissue factor (TF)-initiated thrombin generation independent of TF pathway inhibitor (TFPI) 2018
Risk of cardiovascular death by long-term solid fuel use for cooking and implications of switching to clean fuels: a prospective cohort study of 340,000 chinese adults 2018
The prognostic importance of myocardial fibrosis detected by late-gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) in new-presentation dilated cardiomyopathy (DCM) 2018
When are atrial fibrillation patients at risk to discontinue anticoagulation treatment? Results from the GLORIA-AF Registry 2018
A default in acetyl-CoA carboxylase phosphorylation increases thrombus growth in vitro and in vivo, and in a collagen-dependent manner 2017
A meta-analysis of INR targets for mechanical heart valves: we need new evidence 2017
A novel biomarker-based risk score to predict death in patients with atrial fibrillation: Insights from the ARISTOTLE and RE-LY trials 2017
Changes in thromboembolic risk profile and antithrombotic therapy use over a decade: a comparison of Euro Heart Survey on AF and EURObservational research programme AF pilot registry 2017
Lifestyle risk factors for non-valvular atrial fibrillation 2017
New onset dementia in incident atrial fibrillation. A large cohort study 2017
Predictors of cognitive decline after cardiac surgery: an evaluation of the CABG off or on pump revascularization study (CORONARY) cohort 2017
Steroids in cardiac surgery (SIRS): infection substudy 2017
Surgical ablation of atrial fibrillation evaluation (SAFE): a cost analysis 2017
Women with stable coronary artery disease have better clinical outcomes than men, but this association is modified by degree of depression: insights from the STABILITY trial 2017
Cancer, chronic kidney disease and thrombosis 2016
Changes in BNP prior to major cardiovascular events in patients with type 2 diabetes and a recent coronary event 2016
Evidence based medication use is highly predictive of survival in heart failure patients in Africa, Asia, the Middle East and South America: the INTERCHF Study 2016
Experience with tecarfarin, a novel vitamin K antagonist: use with reversing agents and in mechanical heart valve recipients 2016
Growth differentiation factor 15 is an independent marker of risk of major bleeding in atrial fibrillation: insights from the RE-LY trial 2016
Identification of blood CSF1 and CXCL12 as new causal mediators of coronary artery disease using Mendelian randomization in the ORIGIN trial 2016
Is extraplatelet production of thromboxane B2 in acute myocardial infarction the explanation for higher rates of adverse cardiovascular events? 2016
Observational monocentric registry "CARDIO-STEMI SANREMO": effects of morphine administration in STEMI patients and its association with clinical in-hospital outcomes and long-term mortality 2016
Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation 2016
Predictors of major bleeding in patients with atrial fibrillation treated with rivaroxaban in XANTUS: findings from a real-world prospective study 2016
Prognostic importance of precipitating factors leading to heart failure hospitalization in patients with preserved and reduced ejection fraction: Insights from CHARM 2016
Reversal strategies and outcomes of major bleeding associated with direct oral anticoagulants compared to warfarin in routine practice: interim results from a multi-centre all-comer cohort 2016
Subgroup analysis of patients with concomitant pulmonary embolism in XALIA, a non-interventional study of rivaroxaban in routine treatment of deep vein thrombosis 2016
Surgical ablation of atrial fibrillation ablation in 11 countries: the LAAOS III trial 2016
Thromboxane B2 as a predictor of long-term outcomes in acute myocardial infarction 2016
Vitamin K antagonist control for patients with nonvalvular atrial fibrillation in Eastern and Southeastern Asia: an analysis of event rates from GARFIELD-AF 2016
Adherence to anticoagulant treatment with apixaban and rivaroxaban in a real-world setting 2015
An evaluation of the incidence and prognosis of post coronary artery bypass grafting myocardial infarction according to different definitions in the CORONARY trial 2015
An event driven myocardial infarction definition using troponins after coronary artery bypass surgery in the coronary trial 2015
Application of syncope guidelines in the emergency department do not reduce admission rates: a retrospective cohort study 2015
Association of urinary sodium excretion with blood pressure and cardiovascular clinical events in South America: The PURE study 2015
Associations of hemodynamic load with impaired myocardial flow reserve: role of sex and hypertension 2015
Clinical outcomes of atrial fibrillation patients receiving NSAIDs in the RE-LY trial 2015
Comparative effectiveness of transitional care services in patients discharged from hospital with heart failure: a meta-analysis 2015
Evolving antithrombotic treatment patterns in patients with newly diagnosed atrial fibrillation in GARFIELD-AF 2015
Hypertension and age-specific burden of carotid atherosclerosis in China: results from 25,000 individuals in the China Kadoorie biobank study 2015
Impact of weight reduction on pericardial fat volume and cardiac structure: Implications for atrial fibrillation in a randomized clinical trial 2015
Initial experience with idarucizumab in dabigatran-treated patients requiring emergency surgery or interventon: interim results from the RE-VERSE AD study 2015
Maternal cardiovascular effects of placental dysfunction in the 2nd trimester 2015
Phased array pulmonary vein isolation vs radiofrequency catheter ablation for atrial fibrillation: a non-inferiority systematic review and meta-analysis 2015
Progression to asymptomatic atrial fibrillation as a prognostic index: the Euro Heart Study 2015
Real world usage of direct oral anticoagulants in patients undergoing electrical cardioversion for atrial tachyarrhythmias 2015
Reduction in unnecessary ventricular pacing fails to affect hard clinical outcomes: A meta-analysis 2015
Safety and efficacy of angio-seal vs exo-seal in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction 2015
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for novel oral anticoagulant dose adjustment 2015
Stroke, major bleeding and mortality in newly diagnosed atrial fibrillation with moderate-to-severe chronic kidney disease: results from GARFIELD-AF 2015
The prognostic values of hypoalbuminemia in patients with ST-segment elevation myocardial infarction 2015
Troponin T or I levels following ICD implantation with and without defibrillation testing and their predictive value for outcomes: Insights from the SIMPLE trial 2015
Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial 2014
Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial 2014
Aripazine reverses unfractionated and low molecular weight heparins, fondaparinux and new Xa and IIa oral anticoagulants: report of Phase I/II clinical trial with edoxaban 2014
Association between naps, snore, sleep duration and obesity in the population of INTER-HEART China Study 2014
Combined CT angiographic assessment of area stenosis, lesion length and approach score is superior in prediction of functionally significant coronary stenosis than individual indices alone 2014
Cost effectiveness of device surgery without interruption of oral anticoagulation: results from the bridge or continue warfarin for device surgery randomized controlled trial (Bruise control) 2014
Dabigatran versus warfarin in patients with pacemaker or defibrillator wires in the RE-LY trial: the role of contact activation 2014
Effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized placebo-controlled Study 2014
Immunosuppressive therapy limits myocardial damage and contractile dysfunction in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 2014
International normalized ratio control and 1-year outcomes in patients with newly diagnosed atrial fibrillation: the GARFIELD Registry 2014
Non invasive anatomical and functional assessment of coronary artery disease 2014
Outcome after MI in different socio-economic environments 2014
Statin use reduces incidence of adverse events in patients with atrial fibrillation in the ACTIVE-W, ACTIVE-A and AVERROES studies 2014
Sustained reversal of apixaban anticoagulation with andexanet alfa using a bolus plus infusion regimen in a phase 2 placebo controlled trial 2014
The use of dabigatran according to body mass index: the RE-LY experience 2014
Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II 2014
Truly low-risk patients with newly diagnosed non-valvular atrial fibrillation at risk of stroke: 1-year outcomes from the GARFIELD Registry 2014
Which formula for estimating glomerular filtration rate is the better predictor of outcomes in heart failure with preserved ejection fraction? An analysis from the I-Preserve trial 2014
Community health worker based interventions in secondary prevention of CVD in India (SPREAD): methods and baseline results 2013
Effects of n-3 fatty acids on long-term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction 2013
Efficacy and safety of different bridging regimens of parenteral anticoagulation after mechanical valve replacement 2013
Guidance adherent dabigatran etexilate treatment versus warfarin in the RE-LY population: an analysis on the basis of the European label recommendations for dabigatran etexilate 2013
Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction 2013
Interobserver variability of the SYNTAX score by interventional cardiologists 2013
Long term outcomes of PCI and CABG for isolated proximal LAD lesions: a real world comparison 2013
Management of dyspepsia symptoms on dabigatran during RELY-ABLE: long-term follow up study after RE-LY 2013
One-year outcomes in new versus permanent atrial fibrillation: insights from the prospective, international GARFIELD registry 2013
Physical activity levels, sport activities and risk of acute myocardial infarction: results of the INTERHEART study in China 2013
Randomized trial to examine the effect of ASA dose or ASA dosing frequency on ASA resistance after coronary artery bypass graft surgery 2013
Renal transplant patients have impaired myocardial perfusion independent of the degree of left ventricular hypertrophy: a CMR study 2013
Resting heart rate and decline in cognitive function: observations from the ONTARGET/TRANSCEND studies 2013
Sedation with sevoflurane improves reperfusion in acute myocardial infarction 2013
Twelve-month outcomes in paroxysmal versus permanent atrial fibrillation: data from the prospective, international GARFIELD registry 2013
Antithrombotic therapy for stroke prevention in patients with newly diagnosed atrial fibrillation and a history of acute coronary syndrome: the Global Anticoagulant Registry in the FIELD (GARFIELD) 2012
Atrial fibrillation post myocardial infarction is associated with ventricular fibrillation and poor long term out come 2012
Biventricular dysfunction following administration of anthracycline based chemotherapy in breast cancer: a prospective multi-centre study using advanced cardiac imaging and biochemical markers 2012
Changes in NT-proBNP level after successful PVC ablation in patients without structural heart disease: evidence for PVC-induced chronic wall stress 2012
Changes in left ventricular twist during dobutamine stress echocardiography in patients with myocardial infarction: association with left ventricular reverse remodeling 2012
Effect of apixaban on all-cause mortality in atrial fibrillation: an imputed placebo analysis 2012
Finding cardiac abnormalities in family members of cardiac arrest or sudden death victims through comprehensive clinical and genetic screening: results from the CASPER registry 2012
Impact of renal function on use of antithrombotic therapy in atrial fibrillation: real-world perspective from the global anticoagulant registry in the FIELD registry 2012
Influence of socioeconomic status on Acute Myocardial Infarction (AMI) in China population: the Interheart China study 2012
Left atrial strain relates to surgical indication in patients with severe organic mitral regurgitation: a 2D-speckle tracking study 2012
Left ventricular dyssynchrony induced by chronic right ventricular pacing is associated with long-term poor outcome 2012
Mitral valve morphological abnormalities in severe aortic stenosis - a three-dimensional transesophageal echocardiographic study 2012
Net clinical benefit of apixaban among patients with atrial fibrillation 2012
New insights into the role of thyroid hormones in the severity of right ventricular dysfunction 2012
Prognostic value of electrocardiographic left ventricular hypertrophy in patients with atrial fibrillation 2012
Regional differences in the use of antithrombotic therapy for stroke prevention in atrial fibrillation: European and Asian insights from the Global Anticoagulant Registry in the FIELD (GARFIELD) 2012
Segmental myocardial viability assessment after STEMI: myocardial grid-tagging versus late gadolinium-enhanced magnetic resonance imaging 2012
Analysis of depolarization abnormalities in the evaluation of patients with chest pain 2011
Aortic stiffness is associated with atrial fibrillation recurrence following ablation in lone atrial fibrillation patients 2011
Apixaban in patients with atrial fibrillation and their risk for cardiovascular hospitalization: insights from the AVERROES trial 2011
Atrial remodeling as a consequence of myocardial infarction: beyond left ventricular dysfunction 2011
Cardiac involvement in Wegener granulomatosis resistant to induction therapy 2011
Cardiac outcomes in adults with supravalvar aortic stenosis 2011
Concomitant use of P-glycoprotein inhibitors with dabigatran or warfarin in the RE-LY trial 2011
Dabigatran and warfarin affects the coagulation process at different levels during long-term treatment - a RELY substudy 2011
Differences in baseline electrophysiologic properties and electrical remodeling among pacemaker patients who develop atrial tachyarrhythmias: results of the ASSERT mechanisms of atrial fibrillation St 2011
Effect of dronedarone in patients with permanent atrial fibrillation during the ATHENA study 2011
Efficacy and safety of apixaban compared with aspirin in patients with atrial fibrillation who previously used and discontinued warfarin therapy: a secondary analysis of the AVERROES trial 2011
Efficacy and safety of the novel oral factor Xa inhibitor apixaban in atrial fibrillation (AF) patients with chronic kidney disease (CKD): the AVERROES trial 2011
First use in humans of the new Amigo remote catheter system in electrophysiology studies and catheter ablation for typical atrial flutter 2011
Hypertension control in a large cohort of patients in Poland - preliminary results of the Pol-Fokus study 2011
Importance of algorithm-based warfarin dosing in the quality of anticoagulation control in atrial fibrillation - a multilevel analysis 2011
Influence of location and size of myocardial infarction on post-infarction left ventricular remodelling: an intricate relationship 2011
Predictive value of four-dimensional speckle-tracking longitudinal-strain for the improvement of left ventricular function after acute myocardial infarction 2011
Predictors of atrio-ventricular conduction disease, long term outcomes and a strategy to prevent sudden cardiac death in patients with myotonic dystrophy types 1 and 2 2011
Predictors of early mortality following cardiac resynchronisation therapy 2011
Predictors of regional atrial myocardial fibrosis: implications for obesity atrial fibrillation 2011
Relationship between insulin resistance and progression of left ventricular hypertrophy in patients with aortic stenosis: a substudy of the ASTRONOMER trial 2011
Safe exclusion of deep vein thrombosis in primary and secondary care using the wells-rule; a large individual patient data meta-analysis 2011
Trypanocidal agents for chronic asymptomatic T. cruzi infection: an updated systematic review and meta-analysis 2011
Understanding CRT effects: 2D speckle tracking imaging to monitor the changes in LV systolic activation patterns in responders and non-responders to CRT 2011
Vascular access options in coronary angiography procedures: randomized controlled trial of a patient decision aid 2011
Vendor-independent echocardiographic quantification of left ventricular circumferential strain: validation with cardiovascular magnetic resonance 2011
A novel user-friendly score to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro HeartSurvey 2010
A prospective, long-term, randomized, controlled study of alternate-site right atrial pacing for prevention of atrial fibrillation 2010
Atrial ischemia and the risk of new onset atrial fibrillation development after myocardial infarction 2010
Cardiac involvement in Churg-Strauss syndrome in the disease remission 2010
Catheter ablation for persistent atrial fibrillation ablation: randomised comparison of a new technique with conventional approach 2010
Characterisation of interventricular and intra-left ventricular dyssynchrony in new-onset idiopathic dilated cardiomyopathy, and their response to therapy 2010
Echocardiographic indices of right ventricular systolic function: a cardiac magnetic resonance comparative study 2010
Effect of common cyclooxygenase-2 gene polymorphisms on the long-term outcome after successful single-vessel percutaneous coronary intervention: a pilot study 2010
High dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction 2010
ICD implantations in Australia: age and gender-specific trends from 2000-2008 2010
Late-gadolinium enhancement in new-onset idiopathic dilated cardiomyopathy is associated with recovery of systolic left ventricular function 2010
Left atrial platelet activation is increased in patients with non-valvular lone atrial fibrillation 2010
Left atrial structural remodeling as a consequence of myocardial infarction: relationship to adverse cardiovascular outcome 2010
Metabolic syndrome is associated with faster progression of aortic stenosis: a substudy of the ASTRONOMER trial 2010
Nation-wide trends for atrial fibrillation in Australia: 1998-2008 2010
Prevalence of atrial fibrillation in indigenous australians 2010
Right ventricular ischemic injury in patients with acute ST-segment elevation myocardial infarction - characterization with cardiovascular magnetic resonance 2010
Safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation: a phase II study 2010
The pharmacological inhibition of leukotriene synthesis increases heart rate variability in patients with stable angina and prevents transient prolongation of PQ and QTc intervals caused by coronary a 2010
Thrombus formation in the left atrium in human atrial fibrillation: rate or rhythm related? 2010
Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation 2010
A simple, new risk factor based approach to refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation: The Euro Heart Survey on atrial fibrillation 2009
Accuracy of magnetic resonance dual bolus quantitative myocardial perfusion for determining the myocardial area at risk in chronic coronary artery stenosis 2009
Clinical correlates of myocardial salvage index in acute ST-segment elevation myocardial infarction: a cardiac magnetic resonance imaging study 2009
Combined therapy with angiotensin receptor antagonists and ACE inhibitors versus standard therapy in patients with heart failure: a meta-analysis of randomized controlled trials 2009
D-dimer testing, thrombophilia screening and recurrences in patients with venous thromboembolism: a 6-year follow-up 2009
Euro heart survey on AF: costs of Atrial Fibrillation (AF) for ATHENA-like patients in Greece, Italy, Poland, Spain and the Netherlands 2009
Evaluation of intra-stent neointima hyperplasia in the approach trial (assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history) 2009
Female gender and vascular disease are true risk factors for stroke in patients with atrial fibrillation: data from the Euro Heart Survey 2009
Lead dislodgement and lead related cardiac perforation in ICD patients 2009
Management of atrial fibrillation in the emergency department: are we adhering to guidelines? 2009
Predictors of outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in heart failure with preserved ejection fraction trial (I-PRESERVE) 2009
Prevalence & prognostic importance of micro-& macro-albuminuria in heart failure- an analysis from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Programme 2009
Progression from paroxysmal atrial fibrillation to more sustained forms: clinical correlates and therapeutical consequences 2009
Reduced functional myocardial reserve in patients with severe aortic stenosis. A stress echocardiography study 2009
Serial assessments of coronary remodeling from the approach trial (assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history) 2009
The relationship between left ventricular dyssynchrony and left atrial function in right ventricular pacing 2009
The trade off between device and patient longevity in cost-effective analyses of CRT-D 2009
Validation of contemporary risk stratification schema for predicting stroke and thromboembolism in real world atrial fibrillation patients from the Euro Heart Survey on Atrial Fibrillation 2009
Wide area circumferential ablation for pulmonary vein isolation in patients with atrial fibrillation and pulmonary vein stenosis 2009
A meta-analysis of three pivotal studies of rivaroxaban for thromboprophylaxis after orthopaedic surgery: effect on symptomatic venous thromboembolism, all-cause mortality and bleeding 2008
Age-dependency of regional deformation 2008
Anticoagulant intensity of enoxaparin compared with fondaparinux in the OASIS-5 trial 2008
Cardiac resynchronisation therapy improves diastolic function 2008
Cognitive function and anticoagulation control in patients with atrial fibrillation 2008
Fondaparinux administration according to its European labeling improves outcome in patients with ST elevation acute myocardial infarction (STEMI): a subanalysis of the OASIS-6 study 2008
Health related quality of life in the Irbesartan in heart failure with preserved systolic function trial (I-PRESERVE) 2008
Impact of ramipril on the development of prolonged QT interval: results of the Heart Outcomes Prevention Evaluation (HOPE) study 2008
Impaired exercise capacity is determined by testosterone deficiency and depressive symptoms in men with chronic heart failure 2008
Incomplete inhibition of thromboxane biosynthesis by ASA: determinants and effect on cardiovascular risk 2008
Long-term net clinical benefit in favor of fondaparinux compared with enoxaparin in European patients with non-ST elevation acute coronary syndromes: a subgroup analysis of OASIS-5 2008
Metabolic syndrome is associated with increased global LV afterload in patients with calcific aortic stenosis: results of the ASTRONOMER study 2008
Preoperative BNP measurement for the prediction of low cardiac output syndrome following coronary artery bypass grafting 2008
Randomized double-blind multi-dose trial of the oral factor-Xa inhibitor DU-176b versus LMW Heparin (Dalteparin) for prevention of venous thromboembolism after total hip replacement 2008
Sexual complaints in men with chronic heart failure: prevalence and hormone determinants 2008
Ventricular arrhythmias and sudden death after atrial switch operations for transposition of the great arteries 2008
Assessing concerns about elective cardiac catheterization: the CATH Concern Questionnaire 2007
Autologous Bone marrow-derived stem cell transfer in patients with acute myocardial infarction: one year follow-up results of a randomised, double-blind strain rate imaging study 2007
Autonomic trigger patterns and anti-arrhythmic treatment of atrial fibrillation: data from the Euro Heart Survey 2007
Baseline plasma NT-proBNP concentrations in relation to clinical characteristics: results from the irbesartan in heart failure with preserved systolic function trial 2007
Bleeding risk of Glycoprotein (GP) IIb IIIa inhibitors or thienopyridines with fondaparinux vs. enoxaparin in Acute Coronary Syndromes: insights from the OASIS 5 trial 2007
Both primary and secondary prevention patients receiving their first implantable defibrillator are uncertain but optimistic: results from a pilot investigation 2007
Contemporary therapies for diabetes in the cardiovascular populations of the US and Europe 2007
Cost-effectiveness in France of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome: an analysis using data from OASIS-5 2007
Cost-effectiveness of drug eluting stents in a US setting: cost-utility analysis with a decision analytic model using meta-analysis data with 3 year follow-up 2007
Depression: an ominous co-morbidity in men with chronic heart failure 2007
Discontinuation of clopidogrel within the year following a non-ST-segment elevation acute coronary syndrome has a deleterious effect: evidence from the CURE trial 2007
Disturbed haemostasis predicts mortality in patients with heart failure due to left ventricular systolic dysfunction 2007
Early detection of cardiac effects of pegylated liposomal doxorubicine in elderly breast cancer patients using strain rate imaging 2007
Effect of fondaparinux 2.5 mg once daily on all cause mortality: a meta-analysis of thromboprophylaxis trials 2007
Evaluation of contrast nephropathy in high risk patients undergoing either PCI or diagnostic angiography 2007
Exercise oscillatory ventilation coexisting with increased ventilatory response to exercise identify heart failure patients with very poor outcome 2007
Fondaparinux reduces symptomatic pulmonary embolism and death in patients hospitalized with congestive heart failure: a sub-analysis of the randomized ARTEMIS trial 2007
Iron deficiency: a frequent and morbid condition in patients with chronic heart failure 2007
Is N-acetylcysteine effective for prevention of contrast-induced nephropathy? 2007
NT-pro BNP and diastolic dysfunction by echocardiography predicts cardiovascular outcomes in patients with heart failure and preserved systolic function 2007
Prevalence and determinants of andropausal syndrome in men with chronic heart failure 2007
Preventing contrast-induced nephropathy in high risk patients: does the contrast agent matter? 2007
Risks and patterns of bleeding in patients with atrial fibrillation 2007
The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial 2007
Tracking JNC 7: trends in blood pressure and anti-hypertensive treatments in the US 2007
Weight loss is associated with increased mortality risk in patients with chronic heart failure: evidence from the CHARM program 2007
Additive role of plasma von Willebrand factor levels to clinical risk stratification in patients with atrial fibrillation 2006
Antithrombotic drug prescription and its rationale among general practitioners, internal medicine specialists and cardiologists in The Netherlands. The EXAMINE-AF study 2006
Assessing the risk of T. cruzi positive serology outside of the endemic areas: An index based on the CHICAMOCHA registry in Bucaramanga, Colombia 2006
Benefit of clopidogrel pretreatment before PCI regardless of GP IIb/IIIa inhibitor use 2006
Circulating total testosterone and insulin like growth factor 1 as determinants of haemoglobin level in men with chronic heart failure 2006
Combination high-density lipoprotein infusion and atorvastatin significantly reduces experimental atherosclerosis compared to either therapy alone: serial analysis with high-resolution MRI 2006
Computed tomographic angiography for the grading of coronary collaterals in total occlusions 2006
Detection of baffle leaks by echocardiography in adults after Mustard repair for transposition of the great arteries 2006
Does left atrial scarring determine success in patients undergoing pulmonary vein isolation for atrial fibrillation? 2006
Effect of aerobic versus combined aerobic-resistance training on health-related quality of life in female cardiac patients 2006
Effect of intravenous iron sucrose on exercise tolerance in anaemic and non-anaemic iron deficient patients with chronic heart failure: a randomised, controlled, observer-blinded trial (FERRIC-HF) 2006
Effect of underlying risk of stroke on treatment effects in the ACTIVE-W Trial 2006
Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a systematic review and collaborative meta-analysis of randomized trials 2006
Fasting glucose as a predictor of cardiovascular events in high-risk patients 2006
Fasting plasma glucose and new onset of diabetes type 2 in high-risk patients 2006
Fondaparinux results in less bleeding than enoxaparin, irrespective of heparin use, for patients with acute coronary syndromes 2006
Grade 3 ischemia on the admission electrocardiogram predicts failure of ST resolution and of adequate flow restoration following primary angioplasty for acute myocardial infarction 2006
Guideline adherent antithrombotic treatment is associated with improved outcome compared to undertreatment in real life atrial fibrillation patients 2006
Incidence of stroke in paroxysmal versus persistent/permanent atrial fibrillation and effects of oral anticoagulation or combined antiplatelet therapy: an ACTIVE W substudy 2006
International comparisons of the prevalence of obesity in patients with overt cardiovascular disease 2006
International trends in reaching therapeutic goals for hypertension in diabetics 2006
Iron deficiency frequently occurs in heart failure and predicts exercise intolerance 2006
Late survival of adults with Mustard repair for transposition of the great arteries 2006
Mechano-electrical interaction after atrial switch procedure for complete transposition of the great arteries 2006
Platelet responsiveness to aspirin and cloidogrel and troponin increment after intervention in acute coronary lesions: results of the Practical trial 2006
Predictors of out-of-range INR for patients with atrial fibrillation on oral anticoagulation: results from ACTIVE 2006
Presence of oscillatory ventilation during exercise independently worsens prognosis in patients with stable chronic heart failure 2006
Quantitative troponin predicts cardiogenic shock, sustained ventricular arrthymias, cardiac arrest and reinfarction in non-ST elevation acute coronary syndromes. The GRACE registry 2006
Reduced right ventricular ejection fraction in endurance athletes with symptomatic ventricular arrhythmias. A quantitative angiographic study 2006
Relationship of baseline hemoglobin levels with short term outcome in acute coronary syndromes. Insights from the OASIS 5 and 6 trials 2006
Reperfusion arrhythmia immediately following primary percutanoues coronary intervention for acute ST-segment elevation myocardial infarction predicts short and long-term survival 2006
The cost of atrial fibrillation management in Europe: a cross-sectional study on resource use during admissions and outpatient clinic visits in the Euro Heart Survey cohort 2006
The relationship between metabolic syndrome, according to alternative definitions, and endothelial function among healthy, middle-aged men. The firefighters and their endothelium study 2006
Use of triple and quadruple neurohormonal blockade in heart failure: new data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM)-Added trial 2006
Variations in systolic strain rate and strain parameters: a multiple regression analysis amongst normal individuals 2006
Will implementing a syncope assessment algorithm at emergency room reduce hospital admissions and health care costs? 2006
A randomised blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: the ASPIRE pilot study 2005
Assessment of common and internal carotid artery vessel wall area: a feasibility study using high resolution MRI 2005
Atrial fibrillation carries similar risks in heart failure irrespective of ejection fraction-results from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) 2005
Bundle branch block is associated with worse clinical outcomes in heart failure, especially with reduced systolic function: evidence from the CHARM programme 2005
Determinants of delay in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. The Global Registry of acute coronary events 2005
Diastolic dysfunction in heart failure with preserved systolic function - need for objective evidence. Results from the CHARM Echocardiographic Substudy - CHARMES 2005
Erectile dysfunction in high risk cardiovascular patients - insights from the erectile dysfunction substudy of the ONTARGET/TRANSCEND trials 2005
Factors precipitating heart failure hospitalisation: a novel analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme 2005
Female gender is an independent predictor of better outcome in chronic heart failure: results from the CHARM programme 2005
International and time trends in the use and characteristics of patients with acute coronary syndromes treated with clopidogrel: the global registry of acute coronary events experience 2005
PPARalpha induction in adipose tissue correlates with increased insulin sensitivity and prevention of loss of left ventricular function. Effect of PPARalpha,gamma-agonist in obese dyslipidemic mice 2005
Predictors of quality of life in symptomatic heart failure patients across the left ventricular ejection fraction spectrum 2005
The effect of early education plus bi-weekly telephone nursing consultation on anxiety and health related quality of life in patients waiting for elective cardiac catheterisation 2005
Use of strain and strain rate imaging for early identification of regional myocardial dysfunction in paediatric patients with hypertrophic cardiomyopathy 2005
Vagal and adrenergic atrial fibrillation is found frequently among patients in the Euro Heart Survey 2005
Which factors determine oral anticoagulation prescription in real life atrial fibrillation patients? 2005
Women (especially younger women) with chronic heart failure are less adherent to medication: results from the CHARM program 2005
Women with atrial fibrillation are less aggressively treated than men 2005
A portable ultrasound for rapid evaluation of systolic ventricular function in critically III patients 2004
Automatic referral improves attendance and uptake of cardiac renabilitation after coronary artery bypass graft surgery 2004
Clopidogrel is associated with increased rates of long-term stent thrombosis and mortality as compared to ticlopidine following coronary stent implantation 2004
Early use of low-molecular-weight or unfractionated heparin in patients with non-ST-segment elevation myocardial infarction and unstable angina: the GRACE experience 2004
Guideline-based treatment of acute myocardial infarction in younger and older (75years) patients based on 5123 patients of berlin myocardial infarction registry 2004
Low haemoglobin is associated with more evidence of congestion but less severe systolic dysfunction in patients with chronic heart failure 2004
Response to cardiac rehabilitation after coronary artery bypass graft surgery in patients with and without type 2 diabetes mellitus 2004
Substantial reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials 2004
1854 Magnitude of, and risk factors for, stroke in patients with acute coronary syndromes. The global registry of acute coronary events 2003
2047 Consistent benefit of clopidogrel in patients with non-ST-elevation acute coronary syndromes undergoing very early, early or later percutaneous coronary intervention in the CURE study 2003
2055 Which factors determine the application of reperfusion therapy in ST-elevation acute coronary syndromes? Lessons from the Euro-Heart acute coronary syndromes survey 2003
P1572 In the fibrillating atria the mitochondrial sublimons are significantly correlated with both left atrial diameter and atrial fibrillation duration 2003
P2865 Treating patients with acute coronary syndromes with aggressive anti-platelet agents in the grace registry: no observed decrease in in-hospital mortality but increased bleeding complications 2003
Aspirin dose and bleeding events in the CURE study 2002
Mortality in left ventricular dysfunction treated with angiotensin-converting enzyme inhibitors. Ten-years follow-up post SOLVD close out 2002
The risks versus benefits of clopidogrel treatment in acute coronary syndrome patients overall, and those undergoing CABG: the CURE trial 2002
Accessing tertiary cardiovascular services in a universal, publicly funded health care system. Are some citizens more equal than others? 2001
Direct thrombin inhibitors in acute coronary syndromes: a meta-analysis based on individual patient data 2001
Predictive value of natriuretic peptides and endothelin-1 for LV remodelling in response to candesartan and enalapril: the RESOLVD neurohumoral ancillary study 2001
Stenting and glycoprotein IIb/IIIa inhibition in angioplasty for acute myocardial infarction in the global registry of acute coronary events (GRACE) 2001
Substantial between hospital variation in outcome following first emergency admission for heart failure 2001
Cardiopulmonary results and long-term follow-up of adults with the mustard procedure 2000
OASIS Registry 2-year follow-up: outcomes in patients with unstable angina or myocardial infarction without ST-segment elevation admitted to hospitals with or without catheterisation facilities 2000
Persistence of long-term benefit of hirudin compared to heparin in unstable angina and non-Q-wave infarction 2000
Prognostic importance of weight loss in chronic heart failure and the impact of treatment with ACE inhibitors 2000
Randomized comparison of vasoflux, a novel anticoagulant, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction 2000
Use of abciximab during rescue angioplasty after failed thrombolytic therapy: risk factors for haemorrhagic complications 2000
Concluding remarks 1995
BENEFICIAL-EFFECTS OF NAFAZATROM IN EXPERIMENTAL-MODELS OF CORONARY-THROMBOSIS AND MYOCARDIAL ISCHEMIA 1983
Educational attainment and cardiovascular outcomes in prostate cancer: observations from 3700 men in 6 countries in the RADICAL PC study. 45:ehae666.3159. 2024
Effect of tranexamic acid in vascular surgery- a sub-study of the POISE-3 randomized clinical trial. 45:ehae666.3114. 2024
Mineralocorticoid receptor antagonists for atrial fibrillation prevention: effective solution or empty promise?. ehae687. 2024
In memoriam: Stuart J. Connolly, MD (9 April 1949-2 June 2024).. ehae668. 2024
Great debate: myocardial infarction after cardiac surgery must be redefined.. 45:4170-4177. 2024
Great debate: pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction.. ehae533. 2024
Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials.. ehae596. 2024
Emergency department visit for atrial fibrillation: sex differences in treatment and outcomes in the Global RE-LY AF Registry. 45:2336-2340. 2024
Arm and ankle blood pressure indices, and peripheral artery disease, and mortality: a cohort study. 45:1738-1749. 2024
Embolic strokes of undetermined source: a clinical consensus statement of the ESC Council on Stroke, the European Association of Cardiovascular Imaging and the European Heart Rhythm Association of the ESC. 45:1701-1715. 2024
Urinary thromboxane and risk of cardiovascular events: role of aspirin. 45:1368-1370. 2024
Human papilloma virus and atherosclerotic cardiovascular disease. 45:1083-1085. 2024
Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials. 45:756-774. 2024
Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe. 45:538-548. 2024
Potassium intake: the Cinderella electrolyte. 44:4925-4934. 2023
Endpoint adjudication in cardiovascular clinical trials. 44:4835-4846. 2023
Catheter ablation for atrial fibrillation in patients with heart failure with reduced versus preserved ejection fraction; a systematic review and meta-analysis. 44. 2023
Genetic predisposition to high blood pressure and out-of-office hypertension: insights from a population sample in Liechtenstein. 44. 2023
Heart failure after left atrial appendage occlusion: insights from the LAAOS-III randomized trial. 44. 2023
Long-term recurrence of new-onset post-operative AF in cardiac surgery patients as detected by an implantable loop recorder: a systematic review and individual participant data meta-analysis. 44:ehad655.456. 2023
Sex hormone-binding globulin and heart failure hospitalizations in patients with dysglycemia - Experiences from the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. 44:ehad655.926. 2023
Adverse outcomes in patients with atrial fibrillation: how previous successes can unmask new challenges. 44:4432-4434. 2023
Correction to: 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC). 44:4421-4421. 2023
Frailty and outcomes in heart failure patients from high-, middle-, and low-income countries. 44:4435-4444. 2023
Rapid, accurate publication and dissemination of clinical trial results: benefits and challenges. 44:4220-4229. 2023
Diagnostic management of acute pulmonary embolism: a prediction model based on a patient data meta-analysis. 44:3073-3081. 2023
Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis. 44:3040-3058. 2023
Diet, cardiovascular disease, and mortality in 80 countries. 44:2560-2579. 2023
Lipid distributions in the Global Diagnostics Network across five continents. 44:2305-2318. 2023
Hypertension management in patients with cardiovascular comorbidities. 44:2066-2077. 2023
Multi-level implementation strategies to improve uptake of evidence-based therapies in heart failure. 44:2055-2058. 2023
Leveraging electronic health records to streamline the conduct of cardiovascular clinical trials. 44:1890-1909. 2023
Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. 44:1807-1814. 2023
Reversal agents for current and forthcoming direct oral anticoagulants. 44:1795-1806. 2023
Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study. 44:1157-1166. 2023
Genetic variants associated with syncope implicate neural and autonomic processes. 44:1070-1080. 2023
Improving representativeness in trials: a call to action from the Global Cardiovascular Clinical Trialists Forum. 44:921-930. 2023
Improving precision in estimating diet–disease relationships with metabolomics. 44:570-572. 2023
Factor XI inhibitors: cardiovascular perspectives. 44:280-292. 2023
Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation. 44:208-218. 2023
Bleeding and ischaemic events after first bleed in anticoagulated atrial fibrillation patients: risk and timing. 43:4899-4908. 2022
Corrigendum to: Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. 43:4634-4634. 2022
What is the optimal prosthetic valve in dialysis?. 43:4657-4659. 2022
Sinus rhythm: thesine qua nonfor rhythm control?. 43:4145-4147. 2022
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. 43:3826-3924. 2022
Atrial fibrillation and stroke: who is low risk and what are we going to do about it?. 43:3539-3541. 2022
Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. 43:3512-3527. 2022
Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. 43:3542-3552. 2022
Evaluation of the benefit of rivaroxaban on VOYAGER PAD primary composite of limb, heart and brain outcomes using the global rank and win ratio methods. 43:1971-1971. 2022
Factors associated with health-related quality of life in heart failure in 23,000 patients from 40 countries: results of the global congestive heart failure research program. 43:ehac544.879. 2022
Total hospitalizations after peripheral arterial revascularization in the VOYAGER trial. 43:1982-1982. 2022
Settling the controversy of salt substitutes and stroke: sodium reduction or potassium increase?. 43:3365-3367. 2022
The collateral damage of COVID-19 to cardiovascular services: a meta-analysis. 43:3164-3178. 2022
Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator. 43:3041-3052. 2022
Importance of genetic testing in unexplained cardiac arrest. 43:3071-3081. 2022
Cardiovascular disease, mortality, and their associations with modifiable risk factors in a multi-national South Asia cohort: a PURE substudy. 43:2831-2840. 2022
Modifiable risk factors associated with cardiovascular disease and mortality in China: a PURE substudy. 43:2852-2863. 2022
Risk factors, cardiovascular disease, and mortality in South America: a PURE substudy. 43:2841-2851. 2022
Ethnicity-dependent performance of the Global Registry of Acute Coronary Events risk score for prediction of non-ST-segment elevation myocardial infarction in-hospital mortality: nationwide cohort study. 43:2289-2299. 2022
Ablate and pace for patients with atrial fibrillation: a fragile option?. 43:2160-2160. 2022
Silent brain infarcts impact on cognitive function in atrial fibrillation. 43:2127-2135. 2022
A polypill for cardiovascular disease prevention with a focus on non-alcohol steatohepatitis. 43:2034-2036. 2022
The underrepresentation of female athletes in sports research: considerations for cardiovascular health. 43:1609-1611. 2022
Ciraparantag as a potential universal anticoagulant reversal agent. 43:993-995. 2022
Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score. 43:996-1004. 2022
Anger or emotional upset and heavy physical exertion as triggers of stroke: the INTERSTROKE study. 43:202-209. 2022
Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data. 43:18-28. 2021
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. 42:4040-4048. 2021
Evaluating direct oral anticoagulants versus vitamin K antagonists for treatment of left ventricular thrombus: a systematic review and meta-analysis. 42:ehab724.2981. 2021
Temporal trends in the inclusion of patient-reported outcomes in heart failure randomized trials published in high-impact medical journals: a systematic bibliometric review. 42:ehab724.3171. 2021
Corrigendum to: Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomised trials. 42:3202-3202. 2021
Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality?. 42:3143-3145. 2021
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. 42:2995-3007. 2021
Short-coupled ventricular fibrillation represents a distinct phenotype among latent causes of unexplained cardiac arrest: a report from the CASPER registry. 42:2827-2838. 2021
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. 42:2765-2775. 2021
Exclusion of pregnant and lactating women from COVID-19 vaccine trials: a missed opportunity. 42:2724-2726. 2021
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. 42:2565-2573. 2021
Sodium and health: another challenge to the current dogma. 42:2116-2118. 2021
Alcohol consumption, atrial fibrillation, and cardiovascular disease: finding the right balance. 42:1178-1179. 2021
Medical publishing under review. 42:723-725. 2021
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). 42:373-498. 2021
Peter Sleight, Emeritus Professor of Cardiovascular Medicine, Oxford University, Chairman of the ISIS Trials Steering Committee. 42:221-223. 2021
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. 41:4037-4046. 2020
The obesity paradigm in cardiovascular disease: the need for differentiated weight management. 41:3965-3965. 2020
COVID-19 and Katrina: recalcitrant racial disparities. 41:3390-3393. 2020
Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. 41:3437-3447. 2020
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. 41:3363-3373. 2020
Tracing risk of multiple cardiovascular diseases to smoking-related genes. 41:3311-3313. 2020
Myocardial injury after non-cardiac surgery: diagnosis and management. 41:3083-3091. 2020
Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. 41:2848-2859. 2020
Diet and health: the need for new and reliable approaches. 41:2641-2644. 2020
Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial. 41:2668-2677. 2020
Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. 41:1132-1140. 2020
Risk of stroke and other adverse outcomes in patients with perioperative atrial fibrillation 1 year after non-cardiac surgery. 41:645-651. 2020
Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. 41:231-238. 2020
Flattening the hierarchies in academic medicine: the importance of diversity in leadership, contribution, and thought. 41:9-10. 2020
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. 40:3771-3778a. 2019
Digoxin–mortality: randomized vs. observational comparison in the DIG trial. 40:3336-3341. 2019
288Thrombotic events in bleeding patients treated with andexanet alpha: an ANNEXA-4 sub-study. 40:ehz747.0092. 2019
4112Risk factors and clinical outcomes in chronic CAD and PAD: an analysis of the randomized, double-blind COMPASS trial. 40:ehz745.0116. 2019
P5522ST elevation myocardial infarction networks: relationship of hub-spoke distance with transfer time and clinical outcomes in rescue PCI. 40:ehz746.0470. 2019
P6312Pregnancy outcomes in women with cardiothoracic transplants: a systematic review and meta-analysis. 40:ehz746.0909. 2019
P6351A point-of-care risk score predicts 30-day readmission in patients hospitalized with heart failure (HF): derivation and validation of the LENT index. 40:ehz746.0947. 2019
Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials. 40:3026-3032. 2019
Lifecourse trajectories of body mass index and adult cardiometabolic risk: is childhood a sensitive period?. 40:2920-2920. 2019
Low carb or high carb? Everything in moderation … until further notice. 40:2880-2882. 2019
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. 40:2801-2809. 2019
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. 40:2632-2653. 2019
The heart-brain connection: further establishing the relationship between atrial fibrillation and dementia?. 40:2324-2326. 2019
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. 40:2032-2043. 2019
Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries. 40:1620-1629. 2019
Stroke prevention in AF: Of Asians and non-Asians. 40:1528-1530. 2019
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?. 40:1466-1471. 2019
Canadian spontaneous coronary artery dissection cohort study: in-hospital and 30-day outcomes. 40:1188-1197. 2019
Restrictive compared with liberal red cell transfusion strategies in cardiac surgery: a meta-analysis. 40:1081-1088. 2019
Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. 40:880-886. 2019
Alcohol and Atrial Fibrillation. 40:796-797. 2019
Are the cardiac effects of alcohol good, bad, or neither?. 40:712-714. 2019
An autoantibody identifies arrhythmogenic right ventricular cardiomyopathy and participates in its pathogenesis. 39:3932-3944. 2018
Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). 39:3973-3979. 2018
Assessing the quality of evidence supporting patent foramen ovale closure over medical therapy after cryptogenic stroke. 39:3618-3619. 2018
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. 39:3105-3114. 2018
4940Predicting risk at the point of care: NT-proBNP improves performance of the LACE index among patients hospitalized for Heart Failure (HF). 39:ehy566.4940. 2018
5069Reversal of apixaban and rivaroxaban anticoagulation by andexanet alfa in ANNEXA-A&R as assessed by non-tissue factor (TF)-initiated thrombin generation independent of TF pathway inhibitor (TFPI). 39:ehy566.5069. 2018
P2300Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis. 39:ehy565.p2300. 2018
P2772A novel approach for uric acid crystal detection in human coronary arteries with polarization-sensitive micro-OCT. 39:ehy565.p2772. 2018
P4799When are atrial fibrillation patients at risk to discontinue anticoagulation treatment? Results from the GLORIA-AF Registry. 39:ehy563.p4799. 2018
P5696Electrophysiological characteristics of A1294G substitution in Nav1.5 channel, associated with combined clinical phenotype. 39:ehy566.p5696. 2018
P6066AMPK-ACC signaling modulates platelet phospholipids content and potentiate platelet function and thrombus formation. 39:ehy566.p6066. 2018
P6345Effect of free testosterone levels on cardiovascular outcomes: a Mendelian randomization analysis. 39:ehy566.p6345. 2018
P6544All you need is LE: utility of an abbreviated LACE score in predicting 30-day outcomes among patients hospitalized for Heart Failure (HF). 39:ehy566.p6544. 2018
P836Benzodiazepine-free cardiac anesthesia for reduction of delirium (B-Free): a two-centre pilot study to determine the feasibility of a multi-centre, randomized, cluster crossover trial. 39:ehy564.p836. 2018
Clinical impact of direct stenting and interaction with thrombus aspiration in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: Thrombectomy Trialists Collaboration. 39:2472-2479. 2018
Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. 39:2314-2325. 2018
Epidemiology of atrial fibrillation. 39:1323-1324. 2018
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. 39:750-757a. 2018
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. 39:477-485. 2018
Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. 39:464-473. 2018
The winding path towards rationale anti-thrombotic therapy to prevent stroke in patients with atrial fibrillation. 39:474-476. 2018
Aortic valve replacement in younger patients. 38:3378-3381. 2017
WHF Emerging Leaders Program. 38:2800-2803. 2017
2051A meta-analysis of INR targets for mechanical heart valves: we need new evidence. 38:ehx502.2051. 2017
2202Predictors of cognitive decline after cardiac surgery: an evaluation of the CABG off or on pump revascularization study (CORONARY) cohort. 38:ehx502.2202. 2017
5769Changes in thromboembolic risk profile and antithrombotic therapy use over a decade: a comparison of Euro Heart Survey on AF and EURObservational research programme AF pilot registry. 38:ehx493.5769. 2017
5994Use of drug eluting stents compared to bare metal stents in ST segment elevation myocardial infarction is associated with reduced mortality and cardiovascular outcomes: results from the TOTAL trial. 38:ehx493.5994. 2017
P2748The PROTROPICS feasibility: prognostic value of elevated troponins in critical illness. 38:ehx502.p2748. 2017
P5375A default in acetyl-CoA carboxylase phosphorylation increases thrombus growth in vitro and in vivo, and in a collagen-dependent manner. 38:ehx493.p5375. 2017
P6064Steroids in cardiac surgery (SIRS): infection substudy. 38:ehx493.p6064. 2017
Pitcher perfect: arrhythmia monitoring at the Munich Oktoberfest. 38:2107-2109. 2017
Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis. 38:1509-1516. 2017
Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. 38:1339-1344. 2017
Joint Communication from Davos Cardiology Update, February 2017. 38:1188-1188. 2017
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. 38:1147-1155. 2017
Radial access: how do we interpret subgroup analyses. 38:1081-1083. 2017
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. 38:ehv643-ehv643. 2017
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. 38:ehw069-ehw069. 2017
Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. 38:ehw509-ehw509. 2017
The technical report on sodium intake and cardiovascular disease in low- and middle-income countries by the joint working group of the World Heart Federation, the European Society of Hypertension and the European Public Health Association. 38:ehw549-ehw549. 2017
Imaging atherosclerosis with positron emission tomography. 37:2974-2980. 2016
Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. 37:2882-2889. 2016
Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. 37:1993-2001. 2016
Myocardial blush and microvascular reperfusion following manual thrombectomy during percutaneous coronary intervention for ST elevation myocardial infarction: insights from the TOTAL trial. 37:1891-1898. 2016
Vascular access and antiplatelet therapies: does one influence the other?. 37:1131-1132. 2016
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. 37:1145-1153. 2016
CardioPulse: Prevention of global cardiovascular disease.. 37:505-507. 2016
Prevention of global cardiovascular disease. 37:505-507. 2016
Association between pre-operative statin use and major cardiovascular complications among patients undergoing non-cardiac surgery: the VISION study. 37:177-185. 2016
A 35-year journey to evidence-based medicine: a personal story. 36:3460-3466. 2015
Early performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study. 36:2510-2519. 2015
Stroke in the TOTAL trial: a randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction. 36:2364-2372. 2015
Edoxaban and amiodarone: interactions on multiple levels. 36:2210-2211. 2015
Culprit lesion thrombus burden after manual thrombectomy or percutaneous coronary intervention-alone in ST-segment elevation myocardial infarction: the optical coherence tomography sub-study of the TOTAL (ThrOmbecTomy versus PCI ALone) trial. 36:1892-1900. 2015
Current worldwide nuclear cardiology practices and radiation exposure: results from the 65 country IAEA Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS). 36:1689-1696. 2015
The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring. 36:1640-1642. 2015
CardioPulse ArticlesLeaders in cardiovascular medicineSalim Yusuf MD: the physician who wants to improve the world's cardiovascular healthSpreading the success of cardiovascular medicine worldwideWomen in Cardiology: Elyse Foster MDCentre of excellenceCardiocentro Ticino in Lugano, Switzerland. 36:1560-1565. 2015
Spreading the success of cardiovascular medicine worldwide.. 36:1562-1563. 2015
Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. 36:1454-1462. 2015
Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). 36:1115-1122. 2015
Alcohol consumption and incident cardiovascular disease: not just one unifying hypothesis. 36:897-898. 2015
Mendelian randomization of blood lipids for coronary heart disease. 36:539-550. 2015
Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. 36:669-675. 2015
Hypoplasia of the posterior mitral valve leaflet detected in late adulthood. 36:456-456. 2015
Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. 36:281-288. 2015
Advanced chronic kidney disease in patients undergoing transcatheter aortic valve implantation: insights on clinical outcomes and prognostic markers from a large cohort of patients. 35:2685-2696. 2014
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. 35:2516-2523. 2014
Association of cyclooxygenase-2 genetic variant with cardiovascular disease. 35:2242-2248. 2014
Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. 35:1856-1863. 2014
Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. 35:1743-1751. 2014
Heparin bridging in peri-procedural management of new oral anticoagulant: a bridge too far?. 35:1831-1833. 2014
Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. 35:353-364. 2014
Statistical genetics with application to population-based study design: a primer for clinicians. 35:495-500. 2014
Physical activity in patients with stable coronary heart disease: an international perspective. 34:3286-3293. 2013
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. 34:3137-3144. 2013
Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. 34:3117-3127. 2013
The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. 34:2752-2759. 2013
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. 34:2481-2489. 2013
Community health worker based interventions in secondary prevention of CVD in India (SPREAD): methods and baseline results. 34:P4313-P4313. 2013
Effects of n-3 fatty acids on long-term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. 34:1966-1966. 2013
Efficacy and safety of different bridging regimens of parenteral anticoagulation after mechanical valve replacement. 34:4439-4439. 2013
Management of dyspepsia symptoms on dabigatran during RELY-ABLE: long-term follow up study after RE-LY. 34:p549. 2013
Randomized trial to examine the effect of ASA dose or ASA dosing frequency on ASA resistance after coronary artery bypass graft surgery. 34:P234-P234. 2013
Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. Data from the international CLARIFY registry. 34:P530-P530. 2013
Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?. 34:1630-1635. 2013
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). 34:1498-1505. 2013
Why are we failing to implement effective therapies in cardiovascular disease?. 34:1262-1269. 2013
Salt intake and cardiovascular disease: why are the data inconsistent?. 34:1034-1040. 2013
Another chapter in the story of thrombectomy in ST-elevation myocardial infarction: a story not yet finished. 34:1024-1026. 2013
Atrial fibrillation is associated with increased mortality: causation or association?. 34:1027-1030. 2013
A cardiovascular study that includes a million subjects.. 34:945-946. 2013
Acute management of bleeding in patients on novel oral anticoagulants. 34:489-498. 2013
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. 34:170-176. 2013
CardioPulse Articles. 34:1-6. 2013
Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. 33:2804-2812. 2012
Cardiac outcomes in adults with supravalvar aortic stenosis. 33:2442-2450. 2012
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. 33:2143-2150. 2012
Predictors of long-term benefit of cardiac resynchronization therapy in patients with right bundle branch block. 33:1934-1941. 2012
The hazards of interrupting anticoagulation therapy in atrial fibrillation. 33:1864-1866. 2012
Cognitive impairment and risk of cardiovascular events and mortality. 33:1777-1786. 2012
The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. 33:1750-1757. 2012
Statins: pleiotropic, but less than previously thought. 33:1551-1552. 2012
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?. 33:1049-1057. 2012
Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography. 33:640-648. 2012
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. 33:505-514. 2012
Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study. 33:452-466. 2012
Reducing cardiovascular mortality through lifestyle change in Japan. 33:428-429. 2012
Coronary β2-adrenoreceptors mediate endothelium-dependent vasoreactivity in humans: novel insights from an in vivo intravascular ultrasound study. 33:495-504. 2012
Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials. 33:51-60. 2012
Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. 32:2555-2562. 2011
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. 32:2541-2554. 2011
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. 32:2256-2265. 2011
Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. 32:2135-2142. 2011
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. 32:1854-1864. 2011
Relationship between location and size of myocardial infarction and their reciprocal influences on post-infarction left ventricular remodelling. 32:1640-1648. 2011
Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. 32:1409-1415. 2011
High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. 32:867-877. 2011
A comparison of single-lead atrial pacing with dual-chamber pacing in sick sinus syndrome. 32:686-696. 2011
Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. 32:581-589. 2011
Statins and renovascular disease in the elderly: a population-based cohort study. 32:598-610. 2011
C-reactive protein is a bystander of cardiovascular disease. 31:2092-2096. 2010
C-reactive protein is a mediator of cardiovascular disease. 31:2087-2091. 2010
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. 31:2133-2140. 2010
A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. 31:1730-1736. 2010
Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective. 31:1328-1336. 2010
Novel therapeutic concepts * The epidemic of cardiovascular disease in the developing world: global implications. 31:642-648. 2010
Which antithrombotic to use during PCI?. 31:522-524. 2010
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. 31:50-58. 2010
Big trials, big results, and huge rewards for medicine. 30:1813-1815. 2009
Contrast-enhancing left ventricular apical thrombus. 30:1977-1977. 2009
Ventricular arrhythmias and sudden death in adults after a Mustard operation for transposition of the great arteries. 30:1873-1879. 2009
Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. 30:1440-1449. 2009
Socioeconomic status, blood pressure progression, and incident hypertension in a prospective cohort of female health professionals. 30:1378-1384. 2009
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. 30:900-907. 2009
Improved regional function after autologous bone marrow-derived stem cell transfer in patients with acute myocardial infarction: a randomized, double-blind strain rate imaging study. 30:662-670. 2009
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. 30:655-661. 2009
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. 30:338-345. 2009
Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. 30:152-161. 2009
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. 29:3022-3028. 2008
Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials. 29:2592-2600. 2008
Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. 29:2669-2680. 2008
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. 29:2641-2650. 2008
Association of mitral annular calcification and aortic valve morphology: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study. 29:1542-1547. 2008
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 29:1377-1385. 2008
Diabetes, left ventricular systolic dysfunction, and chronic heart failure. 29:1224-1240. 2008
Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation. 29:1181-1189. 2008
Normal systolic function in hypertrophic cardiomyopathy: reality or myth?: reply. 29:949-949. 2008
Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. 29:932-940. 2008
Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?. 29:915-922. 2008
The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. 29:1057-1071. 2008
Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. 29:632-639. 2008
Cardiac lipoma diagnosed by cardiac magnetic resonance imaging. 29:697-697. 2008
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. 29:315-323. 2008
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. 29:324-331. 2008
New oral anticoagulants in atrial fibrillation. 29:155-165. 2008
Regional myocardial deformation in children with hypertrophic cardiomyopathy: morphological and clinical correlations. 28:2886-2894. 2007
Major bleeding after PCI. Where is our crystal ball?. 28:1917-1919. 2007
Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. 28:1746-1749. 2007
Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. 28:1382-1388. 2007
In vivo cellularization of a cross-linked matrix by intraperitoneal implantation: a new tool in heart valve tissue engineering. 28:1389-1396. 2007
Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. 28:1193-1204. 2007
Anticoagulants in heart disease: current status and perspectives. 28:880-913. 2007
Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. 28:850-856. 2007
Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review. 28:469-477. 2007
Reduced right ventricular ejection fraction in endurance athletes presenting with ventricular arrhythmias: a quantitative angiographic assessment. 28:345-353. 2007
Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. 27:3018-3026. 2006
Apical ballooning syndrome, emotional stress and women: reply. 27:2908-2908. 2006
Lack of efficacy and cost-effectiveness of drug-eluting stents: reply. 27:3076-3076. 2006
Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. 27:2784-2814. 2006
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. 27:2725-2736. 2006
Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?. 27:2154-2157. 2006
Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. 27:1523-1529. 2006
Angiotensin-II receptor blockers and coronary artery disease: 'presumed innocents': reply. 27:1507-1508. 2006
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 27:1447-1458. 2006
Predictors of mortality and morbidity in patients with chronic heart failure. 27:65-75. 2006
Atrial fibrillation management: a prospective survey in ESC Member Countries. 26:2422-2434. 2005
Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. 26:2396-2403. 2005
Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' CollaborationThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. 26:2351-2353. 2005
The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. 26:1369-1378. 2005
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. 26:1063-1069. 2005
Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. 26:1023-1030. 2005
Should brain natriuretic peptides be measured in patients with aortic valve disease?. 26:951-952. 2005
Effect of candesartan on New York Heart Association functional classResults of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 25:1920-1926. 2004
The prevalence of abnormal glucose regulation in patients with coronary artery disease across EuropeThe Euro Heart Survey on diabetes and the heart. 25:1880-1890. 2004
Troponin is more useful than creatine kinase in predicting one-year mortality among acute coronary syndrome patients. 25:2006-2012. 2004
Cross-sectional evaluation of brachial artery flow-mediated vasodilation and C-reactive protein in healthy individuals. 25:1754-1760. 2004
Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. 25:166-181. 2004
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. 25:17-24. 2004
Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. 24:1727-1734. 2003
From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes The Global Registry of Acute Coronary Events (GRACE). 24:1414-1424. 2003
Singapore and coronary heart disease: a population laboratory to explore ethnic variations in the epidemiologic transition. 24:127-129. 2003
Singapore and coronary heart disease: a population laboratory to explore ethnic variations in the epidemiologic transition. 24:127-129. 2003
Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. 23:1771-1779. 2002
Urate levels as a predictor of cardiac deaths: causal relation or mere association?. 23:760-761. 2002
Substantial between-hospital variation in outcome following first emergency admission for heart failure. 23:650-657. 2002
Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. 23:117-123. 2002
Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) Study. 22:103-104. 2001
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. 21:2071-2078. 2000
The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. 21:2033-2041. 2000
Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. 21:1473-1481. 2000
Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. 21:1368-1375. 2000
The impending global epidemic of cardiovascular diseases. 21:880-883. 2000
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. 20:1182-1190. 1999
MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. 20:725-741. 1999
The gap between reliable evidence and adoption of therapies.. 20:637-638. 1999
Study on propionyl-?-carnitine in chronic heart failure. 20:70-76. 1999
Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials. 19:1742-1742. 1998
Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials.. 19 Suppl J:J36-J44. 1998
Digoxin in heart failure: results of the recent digoxin investigation group trial in the context of other treatments for heart failure (vol 18, pg 1685, 1998). 19:675-675. 1998
Erratum. 19:675-675. 1998
Digoxin in heart failure: results of the recent digoxin investigation group trial in the context of other treatments for heart failure. 18:1685-1688. 1997
Treatment for acute myocardial infarction: Overview of randomized clinical trials. 17:16-29. 1996
Heart rate variability: Standards of measurement, physiological interpretation, and clinical use. 17:354-381. 1996
Using exercise endpoints in heart failure trials: design considerations. 17:4-6. 1996
Advances in antithrombotic drug therapy for coronary artery disease. 16:10-21. 1995
Concluding remarks. 16:38-39. 1995
Panel discussion. 15:26-30. 1994
Role of Angiotensin Converting Enzyme Inhibitors in Patients with Left Ventricular Dysfunction and Congestive Heart Failure. 15:9-13. 1994
Panel discussion. 15:26-30. 1994
Effects of -blockers and calcium channel blockers in acute myocardial infarction. 14:18-25. 1993
Preserved left ventricular function during supine exercise in patients after orthotopic cardiac transplantation. 13:321-329. 1992
Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients. 12:1225-1233. 1991
Use of impedance cardiography in evaluating the exercise response of patients with left venticular dysfunction. 6:1016-1024. 1985
Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. 6:556-585. 1985
Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. 6:199-226. 1985
The entry ECG in the early diagnosis and prognostic stratification of patients with suspected acute myocardial infarction. 5:690-696. 1984
Comparative response of male and female patients with coronary artery disease to exercise rehabilitation. 5:649-651. 1984

European Heart Journal Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)